25 Январь, 2003
.DELTA.9 Tetrahydrocannabinol (.DELTA.9 THC) solution metered dose inhaler (Assignee -- Virginia Commonwealth University)
Abstract: The present invention provides therapeutic formulations for solutions of .DELTA..sup.9 -tetrahydrocannabinol to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of .DELTA.. U.S. Patents via NewsEdge Corporation : Abstract: The present invention provides therapeutic formulations for solutions of .DELTA..sup.9 -tetrahydrocannabinol (.DELTA..sup.9 THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of .DELTA..sup.9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders. Ex Claim Text: A pharmaceutical composition consisting essentially of 1,1,1,2,3,3,3-heptafluoropropane (HFA 227), .DELTA..sup.9 -tetrahydrocannabinol, and up to 15 percent by weight of an organic solvent, said .DELTA..sup.9 -tetrahydrocannabinol and said organic solvent being dissolved in said HFA 227 to form a stable composition, wherein said .DELTA..sup.9 -tetrahydrocannabinol is present in said composition in concentrations ranging from 0.147% w/w (.+-.0.008) to 5.940% w/w (.+-.0.191). Patent Number: 6509005 Issue Date: 2003 01 21 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Inventor(s): Peart, Joanne Byron, Peter R. Lichtman, Aron H. Martin, Billy R. << Copyright ©2003 MicroPatent >>
23 Январь, 2003
Finding Cures for Manic Depression/ Prechter Fund Awards $500,000 To Researchers at Massachusetts General Hospital
DETROIT, Jan. 23 /PRNewswire/ -- Waltraud "Wally" Prechter, founder and president of the Heinz C. PR via NewsEdge Corporation : DETROIT, Jan. 23 /PRNewswire/ -- Waltraud "Wally" Prechter, founder and president of the Heinz C. Prechter Fund for Manic Depression, announced today a $500,000 grant to researchers at Massachusetts General Hospital (MGH) to help find cures for manic depression, also known as bipolar disorder. The funds will be used to establish the "Prechter Center for the Study of Genetics of Pediatric Bipolar Disorders." MGH serves as a teaching hospital for Harvard Medical School and was ranked the best hospital for psychiatry in the United States in U.S. World and News Report of 2001. Dr. Joseph Biederman, chief of MGH's Pediatric Psychopharmacology Research Program and professor of psychiatry at Harvard Medical School, heads the research team. The team will receive $500,000 over a two-year period to conduct research of children suffering from manic depression. Dr. Biederman's team will launch one of the largest long-term genetics studies in pediatric bipolar disorder by analyzing over 1,600 DNA samples from children afflicted by manic depression and their related family members. The researchers set out to identify the genes responsible for manic depression. In addition, they hope to determine which genes affect how children respond to specific medications. "We are excited to partner with one of the leading bipolar research teams in the nation," said Prechter. "Dr. Biederman and his colleagues will be instrumental in identifying the genetic underpinnings of the insidious hereditary disease of manic depression. We are confident that Dr. Biederman's research will lead to better diagnostic tools, improved treatment options and -- ultimately -- cures for manic depression." "We are honored that the Prechter Fund would make its first major gift to us," said Biederman. "We fully share the vision of the Prechter family to help develop cures for manic depression. Through the Prechter Center we honor the family of a man who made a tremendous difference in this world -- and continues to do so." Prechter established the non-profit Heinz C. Prechter Fund for Manic Depression in memory of her late husband to advance breakthrough medical research to help develop cures for bipolar disorder. Industrialist Heinz Prechter introduced the sunroof to America and built his one-man enterprise into a global group of companies. He suffered from intermittent bouts of manic depression for most of his adult life and fell victim to suicide at the age of 59 in July 2001. Since then, Prechter has emerged as one of the most outspoken and effective mental health advocates in the United States. She provided testimony before Congress to increase the federal funding for bipolar disorder research and was appointed by President George W. Bush to the New Freedom Commission on Mental Health to help improve the mental health care system in the United States. Moreover, the Prechter Fund raised over $1.25 million at its first gala dinner in October 2002 turning the event into the largest single fund-raising event for manic depression in U.S. history. Manic depression affects an estimated 2.7 million adult Americans. As debilitating as blindness or paraplegia, manic depression adds significantly to the overall economic burden of mental disorders of $170 billion a year in health care expenditures and economic loss due to lost productivity, absenteeism and premature death. An estimated 730,000 Americans attempt suicide every year with close to 30,000 of them completing the horrific act, that is one suicide every 17 minutes. Nearly 70 percent of suicides are depression related. SOURCE Heinz C. Prechter Fund for Manic Depression -0- 01/23/2003 /CONTACT: Stephan Koller, Executive Director of Heinz C. Prechter Fund for Manic Depression, +1-734-246-0056; Susan McGreevey of Massachusetts General Hospital, +1-617-724-2764/ CO: Heinz C. Prechter Fund for Manic Depression; Massachusetts General ST: Michigan, Massachusetts IN: MTC HEA SU: NPT TH-ML -- DETH019 -- 7480 01/23/2003 13:29 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>
22 Январь, 2003
Пополнение в разделе Пособия

В разделе пособия для врачей размещена лекция "Сосудистые психозы" канд.мед.наук доц. кафедры психиатрии ЦОЛИУВ (ныне РМАПО) Видмановой Л.Н. В работе излагаются вопросы клиники, дифференциальной диагностики и терапии психических расстройств при сосудистых заболеваниях головного мозга.

22 Январь, 2003
Researchers Discover Anxiety and Aggression Gene in Mice - /CAUTION -- ADVANCE FOR RELEASE AT 6 A.M. EST THURSDAY, JAN. 23/
/ADVANCE/ CLEVELAND, Jan. 22 /PRNewswire/ -- Researchers report finding a gene that is essential for normal levels of anxiety and aggression. PR via NewsEdge Corporation : /ADVANCE/ CLEVELAND, Jan. 22 /PRNewswire/ -- Researchers report finding a gene that is essential for normal levels of anxiety and aggression. Calling it the Pet-1 gene, researchers at the Case Western Reserve University School of Medicine Department of Neurosciences say that when this gene is removed or "knocked out" in a mouse, aggression and anxiety in adults are greatly elevated compared to a control (also called wild type) mouse. Other neurologic functions, such as motor coordination, feeding, and locomotor activity, do not appear altered in the knockout mouse. Anxiety and aggression are normal and important behaviors that allow individuals to respond appropriately to threats or cope with a challenging environment. However, it is clear that uncontrollable or excessive anxiety and aggression can be counterproductive. "The Pet-1 knockout mouse we've made is very likely to represent a new model for gaining a greater understanding of human disorders characterized by heightened anxiety and violence," says Evan Deneris, Ph.D., principal investigator of the study and a neuroscientist at CWRU. The study is published in the Jan. 23 issue of the science journal Neuron. Previously, Deneris' lab showed that in the brain, Pet-1 is active only in serotonin nerve cells or neurons, a relatively small number of cells (among the trillions of neurons in a human brain, only a few hundred thousand produce serotonin) that profoundly affect emotions. Serotonin is a chemical that acts as a messenger or neurotransmitter allowing neurons to communicate with one another in the brain and spinal cord. It is important for ensuring an appropriate level of anxiety and aggression. Defective serotonin neurons have been linked to excessive anxiety, impulsive violence, and depression in humans. Antidepressant drugs such as Prozac and Zoloft work by increasing serotonin activity and are highly effective at treating many of these disorders. But it is unknown why some people have dysfunctional serotonin neurons and whether this can be caused by defects in genes that are normally required for their early development. "We have now shown that Pet-1 is required specifically for fetal development of serotonin neurons," says Deneris. In mice missing this gene, most serotonin neurons fail to be generated in the fetus and the ones that remain are defective. This leads to very low serotonin levels throughout the developing brain, which in turn results in altered behavior in adults. "This is the first gene shown to impact adult emotional behavior through specific control of fetal serotonin neuron development." Deneris and his colleagues employed sensitive tests of aggression and anxiety to compare the behavior of the knockout mice to wild type mice. One such aggression test measures a mouse's response time to an intruder mouse entering its territory. The Pet-1 knockout mice attacked intruders much more quickly and more often than wild type mice. In fact, knockout mice often would not engage in normal exploratory behavior directed toward the intruder before attacking it. Excessive anxiety-like behavior was evident in another test, measuring the amount of time a mouse spends in open unprotected areas of a test chamber compared to closed protected areas. Unlike normal mice, which will enter and explore an unprotected portion of the test chamber, the Pet-1 knockout mice avoided this area all together, indicating abnormal anxiety-like behavior. The human and mouse serotonin systems share many anatomical and functional features, and the same Pet-1 gene is present in the human genome. Therefore, Deneris' discovery creates the first animal model for gaining a greater understanding of the causes of abnormal anxiety and aggression brought about through defective early serotonin neuron development. Deneris also sees this knockout mouse being used as a model for screening new drugs that can treat both aggression and anxiety. "If in fact particular genetic variants of Pet-1 are associated with excessive anxiety or violent activity in humans, then tests to detect these variants might be useful for early diagnosis of people who may be at risk for developing these abnormal behaviors," Deneris says. His lab plans more studies in mice to see how the gene affects sleep-wake patterns, learning and memory, and sexual behavior - all functions controlled in part by serotonin. Lead authors on the study are Timothy J. Hendricks, and Dmitry V. Fyodorov, who were graduate students in Deneris's lab at the time of the study. Other authors are, from CWRU: Lauren J. Wegman, Nadia B. Lelutiu, Elizabeth A. Pehek, Ph.D., Bryan Yamamoto, Ph.D., and Jerry Silver, Ph.D.; and, from Baylor College of Medicine, Edwin J. Weeber, Ph.D., and J. David Sweatt, Ph.D. SOURCE Case Western Reserve University School of Medicine -0- 01/23/2003/0600 /NOTE TO EDITORS: Videos displaying aggressive behavior of Pet-1 knockout mice can be viewed at http://neurowww.cwru.edu/faculty/deneris.shtml; click Movies Link./ /CONTACT: George Stamatis, Director, Public Affairs of Case Western Reserve University School of Medicine, +1-216-368-3635/ /Web site: http://www.cwru.edu/ CO: Case Western Reserve University School of Medicine ST: Ohio IN: HEA MTC SU: BG-LA -- CLW024 -- 5790 01/22/2003 14:38 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>
20 Январь, 2003
Диссертации:

на заседании диссертационного совета НЦПЗ РАМН состоялась защита кандидатской диссертации

28 Декабрь, 2002
Острые эндогенные психозы - Пападопулос Т.Ф.

Острые эндогенные психозы - Пападопулос Т.Ф.

26 Декабрь, 2002
HUMAN SCHIZOPHRENIA GENE
Abstract: Nucleic acids comprising the neuregulin 1 gene and encoding NRG1 polypeptides are disclosed. European Patents via NewsEdge Corporation : Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Pub. No.: EP 1265999 Appl. Data: EP 01913147 2001 02 28 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Decode Genetics EHF. << Copyright ©2002 MicroPatent >>
21 Декабрь, 2002
Autism cases show increase
Barbara Bibbo' 12/21/2002 Autism is affecting an increasing number of children in the UAE, despite greater attention and new measures taken by the local authorities to stem the problem, said local experts. Gulf News via NewsEdge Corporation : Barbara Bibbo' 12/21/2002 Autism is affecting an increasing number of children in the UAE, despite greater attention and new measures taken by the local authorities to stem the problem, said local experts. The disability which about 10 years ago in the UK was affecting 10 children in 10,000, is today detected in 63 out of 10,000, and the trend in the UAE is likely to mimic the international increase. According to Dr Derrick Smith, psychiatrist at the University of British Columbia, currently visiting the UAE, the increase is not only due to higher awareness about autism which contributes to detecting a bigger number of cases, but to a probable increase in the spectrum of the risk factors which scientific researches are trying to bring to surface. Although the UAE has no official studies on the incidence of autism in the country, an increased number of cases has led to the opening of five new centres in the last two years, a local expert added. Dr Mowafaq Mustafa, Deputy Director of the Abu Dhabi Future Centre, which hosts some patients, said that increased attention by the UAE authorities is contributing to dispel the confusion and ignorance about the disability, which was prevalent just two years ago. "Many centres have been opened in the last two years to treat autistic patients, including the Sharjah and Dubai centres for Autism, the Abu Dhabi Red Crescent's centre, the Abu Dhabi Sheikha Shamsa's centre and the Abu Dhabi Educational Zone Centre. "Knowledge about the disease is increasing but more has to be done to help these patients, since behavioural treatment which is very long and expensive is to date the only effective way to stem the problem." Speaking on the sidelines of a conference on autism the two specialists said the UAE could have a number of cases which remain undetected, since the disability is easily misdiagnosed. The conference was sponsored by Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Higher Education and Scientific Research and honourary president of the Future Centre. "Autistic children reveal a wide spectrum of symptoms including attention deficit, social interaction problems, communication difficulties, in some cases hyperactivity and delay in the motor skills." Dr Smith added: "The main cause is genetic, but many other factors can contribute to the disorder to reveal itself like exposure to radiations, viral infections during pregnancy, lack of oxygen during childbirth, meningitis, brain infection, and others. Nevertheless, in many cases the cause remains unknown." According to him detection of the disability is often delayed, because the symptoms are mistaken for bad social behaviour. Patients are blamed of abnormal social conduct or mental retardation and this jeopardises their capability of playing a role in society forever. "Early detection and intensive behavioural treatment can help the patients to run almost a normal life, although they will never recover completely. Behavioural therapy is very long and expensive, requiring a one to one interaction with a therapist and up to 40 hours a week exercise with the patients." Dr Smith, who is in the UAE on a special visit to promote awareness, also assessed some cases. He announced the preparation of a visit by some international experts to be in the UAE in February next year to continue the awareness campaign on the disability. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
19 Декабрь, 2002
Wyeth's Effexor XR significantly relieves physical and emotional symptoms of depression and generalized anxiety disorder.
12/11/2002 Wyeth Pharmaceuticals announced that the serotonin-norepinephrine reuptake inhibitor antidepressant Effexor XR significantly relieved patients' physical and emotional symptoms related to depression and generalized anxiety disorder , according to data presented at an annual scientific meeting of neuropsychopharmacologists. Chemical Business NewsBase - Press Release via NewsEdge Corporation : 12/11/2002 Wyeth Pharmaceuticals announced that the serotonin-norepinephrine reuptake inhibitor antidepressant Effexor XR (venlafaxine HCl) significantly relieved patients' physical and emotional symptoms related to depression and generalized anxiety disorder (GAD), according to data presented at an annual scientific meeting of neuropsychopharmacologists. Effexor XR is believed to increase levels of both serotonin and norepinephrine, two of the brain chemicals thought to be implicated in depression and generalized anxiety disorders. Effexor XR was significantly effective in treating GAD patients' physical and emotional symptoms and equally effective regardless of the initial severity of physical symptoms, according to three pooled analyses of 1841 GAD patients in five double-blinded studies. Moreover, 767 GAD patients treated with Effexor XR and followed for six months demonstrated continued improvement across the spectrum of symptoms beyond their first eight weeks of therapy. Also, in depression patients, Effexor XR demonstrated greater therapeutic effect than selective serotonin reuptake inhibitors fluoxetine, paroxetine, and fluoxamine regardless of the severity of physical and emotional symptoms, according to two other pooled analyses of eight randomised, double-blind studies in 2045 patients. Patients with untreated or under-treated depression and GAD may suffer from an array of physical (somatic) and emotional (psychic) symptoms. Effexor XR was discovered and developed by Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth. The product is also marketed by Wyeth Pharmaceuticals. The immediate-release formulation was approved by the FDA in 1993; the extended-release (XR) formulation was approved in 1997. These medications are available only by prescription. Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, haemophilia, oncology and vaccines. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
18 Декабрь, 2002
Warning that diet pills can lead to depression, suicide
12/18/2002 Overweight people have been warned that using diet pills containing amphetamine agents can cause depression and even lead to suicide. Bangkok Post via NewsEdge Corporation : 12/18/2002 Overweight people have been warned that using diet pills containing amphetamine agents can cause depression and even lead to suicide. Dr Apichai Mongkol, deputy director-general of the Mental Health Department, said shedding kilos by taking diet pills with methamphetamine substances for a long time would badly affect one's health. Side-effects of the pills included sleeping problems, loss of appetite and a lack of serotonin, which could lead to depression and even suicide, he added. There were no statistics on the number of people suffering mental illnesses from taking diet pills as people did not divulge this to psychiatrists, he said. About 1% of the Thai population of 62 million suffers from mental problems of some sort. Dr Apichai suggested overweight people set themselves clear goals to lose 2kg a year, and reward themselves occasionally by eating a favourite food, instead of using diet pills. Public Health Minister Sudarat Keyuraphan said the recent death of a diet-pill user in Ang Thong was a lesson for teenagers and women who resorted to medication to lose weight. The use of diet pills should be closely monitored by doctors or it could be harmful since such medicines affected the nervous system as well, she said. Mrs Sudarat called on those with weight problems to exercise for 30 minutes at least three times a week, and eat more fruit and vegetables instead of sweet and fatty food. Food and Drug Administration deputy secretary-general Dr Sathaporn Wongcharoen said diet pills were dangerous because they contained amfepramone, phentermine, mazindol and cathine which affected the central nervous system and could cause coronary diseases in the long run. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>